# TherapeuticsMD, Inc.: financial statements, quarterly

TXMD · Nasdaq · CIK 25743 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/txmd.md) · [Financials](/companies/txmd/financials.md) · [Filings](/companies/txmd/filings.md) · [Insiders](/companies/txmd/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/txmd/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | period not labelled (2024-03-31) | Q2 FY2024 (2024-06-30) | period not labelled (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [(53.0)](/filings/0001193125-23-277143.md) | [502 d](/filings/0001013762-25-003442.md) | [313](/filings/0001213900-25-042697.md) | [234](/filings/0001213900-25-075003.md) | [547](/filings/0001213900-25-109381.md) | [667 d](/filings/0001013762-25-003442.md) | [393](/filings/0001213900-26-055081.md) | [952](/filings/0001213900-26-087768.md) | [784](/filings/0001213900-25-109381.md) | [893 d](/filings/0001213900-26-037918.md) | [724](/filings/0001213900-26-055081.md) | [869](/filings/0001213900-26-087768.md) |
| Cost of revenue | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Gross profit | $k | [(53.0)](/filings/0001193125-23-277143.md) | [502 d](/filings/0001213900-24-028003.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Selling, general and administrative | $k | [1,590](/filings/0001193125-23-277143.md) | [1,476 d](/filings/0001013762-25-003442.md) | [1,322](/filings/0001213900-25-042697.md) | [1,582](/filings/0001213900-25-075003.md) | not reported | not reported | [1,081](/filings/0001213900-25-042697.md) | [1,551](/filings/0001213900-25-075003.md) | not reported | not reported | not reported | not reported |
| Operating income | $k | [(1,773)](/filings/0001193125-23-277143.md) | [(1,611) d](/filings/0001013762-25-003442.md) | [(1,142)](/filings/0001213900-25-042697.md) | [(2,789)](/filings/0001213900-25-075003.md) | [(1,134)](/filings/0001213900-25-109381.md) | [(652) d](/filings/0001213900-26-037918.md) | [(1,281)](/filings/0001213900-26-055081.md) | [(695)](/filings/0001213900-26-087768.md) | [(862)](/filings/0001213900-25-109381.md) | [(1,552) d](/filings/0001213900-26-037918.md) | [(723)](/filings/0001213900-26-055081.md) | [(816)](/filings/0001213900-26-087768.md) |
| Interest expense | $k | [20.0](/filings/0001193125-23-277143.md) | [185 d](/filings/0001213900-24-028003.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $k | not reported | not reported | not reported | not reported | not reported | not reported | [(32.0)](/filings/0001213900-26-055081.md) | [0.0 d](/filings/0001213900-26-087768.md) | [0.0 d](/filings/0001213900-25-109381.md) | not reported | not reported | not reported |
| Net income | $k | [(3,378)](/filings/0001193125-23-277143.md) | [(883) d](/filings/0001013762-25-003442.md) | [(734)](/filings/0001213900-25-109381.md) | [(1,090)](/filings/0001213900-25-109381.md) | [(609)](/filings/0001213900-25-109381.md) | [252 d](/filings/0001213900-26-037918.md) | [(653)](/filings/0001213900-26-087768.md) | [551](/filings/0001213900-26-087768.md) | [152](/filings/0001213900-25-109381.md) | [(619) d](/filings/0001213900-26-037918.md) | [95.0](/filings/0001213900-26-087768.md) | [155](/filings/0001213900-26-087768.md) |
| Diluted EPS | $ per share | [(0.32)](/filings/0001193125-23-277143.md) | not reported | [(0.06)](/filings/0001213900-25-042697.md) | [(0.09)](/filings/0001213900-25-075003.md) | [(0.05)](/filings/0001213900-25-109381.md) | not reported | [(0.06)](/filings/0001213900-26-055081.md) | [0.05](/filings/0001213900-26-087768.md) | [0.01](/filings/0001213900-25-109381.md) | not reported | [0.01](/filings/0001213900-26-055081.md) | [0.01](/filings/0001213900-26-087768.md) |
| Basic EPS | $ per share | [(0.32)](/filings/0001193125-23-277143.md) | not reported | [(0.06)](/filings/0001213900-25-042697.md) | [(0.09)](/filings/0001213900-25-075003.md) | [(0.05)](/filings/0001213900-25-109381.md) | not reported | [(0.06)](/filings/0001213900-26-055081.md) | [0.05](/filings/0001213900-26-087768.md) | [0.01](/filings/0001213900-25-109381.md) | not reported | [0.01](/filings/0001213900-26-055081.md) | [0.01](/filings/0001213900-26-087768.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, us-gaap:Revenues, us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
- Cost of revenue: not reported
- Gross profit: us-gaap:GrossProfit
- Research and development: not reported
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | period not labelled (2024-03-31) | Q2 FY2024 (2024-06-30) | period not labelled (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [10.2](/filings/0001193125-23-277143.md) | [4.3](/filings/0001013762-25-003442.md) | not reported | not reported | not reported | [5.1](/filings/0001213900-25-042697.md) | [5.7](/filings/0001213900-25-042697.md) | not reported | not reported | not reported | not reported | not reported |
| Current assets | $m | [17.4](/filings/0001193125-23-277143.md) | [11.8](/filings/0001013762-25-003442.md) | not reported | [11.8](/filings/0001213900-24-067771.md) | not reported | [12.3](/filings/0001213900-26-037918.md) | [12.5](/filings/0001213900-25-042697.md) | [13.5](/filings/0001213900-25-075003.md) | [14.5](/filings/0001213900-25-109381.md) | [14.4](/filings/0001213900-26-087768.md) | [15.3](/filings/0001213900-26-055081.md) | [16.1](/filings/0001213900-26-087768.md) |
| Total assets | $m | [50.5](/filings/0001193125-23-277143.md) | [43.3](/filings/0001013762-25-003442.md) | not reported | [40.1](/filings/0001213900-24-067771.md) | not reported | [38.8](/filings/0001213900-26-037918.md) | [38.2](/filings/0001213900-25-042697.md) | [38.5](/filings/0001213900-25-075003.md) | [38.7](/filings/0001213900-25-109381.md) | [37.7](/filings/0001213900-26-087768.md) | [37.6](/filings/0001213900-26-055081.md) | [37.5](/filings/0001213900-26-087768.md) |
| Current liabilities | $m | [14.5](/filings/0001193125-23-277143.md) | [6.9](/filings/0001013762-25-003442.md) | not reported | [5.8](/filings/0001213900-24-067771.md) | not reported | [5.2](/filings/0001213900-26-037918.md) | [4.7](/filings/0001213900-25-042697.md) | [4.7](/filings/0001213900-25-075003.md) | [4.9](/filings/0001213900-25-109381.md) | [4.8](/filings/0001213900-26-087768.md) | [4.9](/filings/0001213900-26-055081.md) | [5.0](/filings/0001213900-26-087768.md) |
| Total liabilities | $m | [22.4](/filings/0001193125-23-277143.md) | [14.0](/filings/0001013762-25-003442.md) | not reported | [12.5](/filings/0001213900-24-067771.md) | not reported | [11.5](/filings/0001213900-26-037918.md) | [11.5](/filings/0001213900-25-042697.md) | [11.2](/filings/0001213900-25-075003.md) | [11.2](/filings/0001213900-25-109381.md) | [10.8](/filings/0001213900-26-087768.md) | [10.6](/filings/0001213900-26-055081.md) | [10.4](/filings/0001213900-26-087768.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [28.1](/filings/0001193125-23-277143.md) | [29.3](/filings/0001213900-26-037918.md) | [28.7](/filings/0001213900-25-109381.md) | [27.7](/filings/0001213900-25-109381.md) | [27.1](/filings/0001213900-25-109381.md) | [27.4](/filings/0001213900-26-087768.md) | [26.7](/filings/0001213900-26-087768.md) | [27.3](/filings/0001213900-26-087768.md) | [27.4](/filings/0001213900-25-109381.md) | [26.9](/filings/0001213900-26-087768.md) | [27.0](/filings/0001213900-26-087768.md) | [27.1](/filings/0001213900-26-087768.md) |

- Cash and equivalents: us-gaap:Cash, us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | period not labelled (2024-03-31) | Q2 FY2024 (2024-06-30) | period not labelled (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(6,028) d](/filings/0001193125-23-277143.md) | [(4,960) d](/filings/0001013762-25-003442.md) | [(229)](/filings/0001213900-25-042697.md) | [1,453 d](/filings/0001213900-25-075003.md) | [(71.0) d](/filings/0001213900-25-109381.md) | [17.0 d](/filings/0001213900-26-037918.md) | [699](/filings/0001213900-26-055081.md) | [381 d](/filings/0001213900-26-087768.md) | [999 d](/filings/0001213900-25-109381.md) | [375 d](/filings/0001213900-26-037918.md) | [944](/filings/0001213900-26-055081.md) | [779 d](/filings/0001213900-26-087768.md) |
| Capital expenditure | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
- Capital expenditure: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | period not labelled (2024-03-31) | Q2 FY2024 (2024-06-30) | period not labelled (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [9.3](/filings/0001193125-23-277143.md) | [9.8](/filings/0001193125-23-145064.md) | [10.2](/filings/0001213900-24-067771.md) | [10.7](/filings/0001193125-23-277143.md) | [11.5](/filings/0001213900-25-042697.md) | [11.5](/filings/0001213900-25-075003.md) | [11.5](/filings/0001213900-25-109381.md) | [0.0](/filings/0001213900-26-055081.md) | [11.6](/filings/0001213900-26-087768.md) | [11.6](/filings/0001213900-25-109381.md) | [0.0](/filings/0001213900-26-055081.md) | [11.6](/filings/0001213900-26-087768.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 11,574,362 at 2026-08-09, from the cover of the [10-Q filed 2026-08-11](/filings/0001213900-26-087768.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:18 ET. No prices; not investment advice.